Hemophilia Patient Resources

Find a Helixate^® FS representative

To locate a Helixate^® FS representative near you contact Consumer Affairs:

Phone: 888-508-6978
Fax: 610-878-4008

Enter your ZIP code to to send a message to your local Helixate FS representative:

Submit

For technical and medical questions about Helixate^® FS, please call the CSL Behring Medical Affairs Department at 1-800-504-5434.

HTC/Chapter Locator

The CDC supports a network of specialized healthcare centers to prevent and reduce complications experienced by persons with certain blood disorders including hemophilia A, hemophilia B, and von Willebrand disease.

The Hemophilia Foundation has created The Chapter Center with information regarding the Chapter nearest you.

AllAboutBleeding-us.com

AllAboutBleeding-us.com is an online resource dedicated to increasing awareness about hemophilia. You'll find information about hemophilia, a community of people sharing their experiences, plus an expert to answer questions about hemophilia.

Visit AllAboutBleeding-us.com

Frequently Asked Questions

There are plenty of questions about hemophilia. Click here to find answers for many of them.

Glossary

Click here to access a glossary of hemophilia terms

Next: FAQ »

Important Safety Information

Helixate^® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Helixate^® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to antihemophilic factor. The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.

Helixate^® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

Please see the full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.